Clinical Trial: An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy

U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT07573631) titled 'An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy' on April 17.

Brief Summary: This open-label extension study aims to evaluate the long-term safety and tolerability of weekly BMN 351 infusions, as well as to assess the effect of BMN 351 on physical function, in participants with DMD who participated in the 351-201 study.

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Duchene Muscular Dystrophy

Intervention: DRUG: BMN 351

Anti-sense Oligonucleotide BMN 351 will be administered intravenously

Recruitment Status: ENROLLING_B...